Anti-viral azide containing compounds

Patent metadata

Field	Value
Publication number	US-10632133-B2
Application number	US-201715834639-A
Country	US
Kind code	B2
Filing date	Dec 7, 2017
Priority date	Jul 28, 2010
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

First claim

What is claimed:

1. A method of treating a subject infected with a plant, an insect or an animal virus and in need of treatment for the infection, the method comprising administering to the subject a therapeutically effective amount of an azide-modified carbohydrate or pharmaceutically acceptable salt thereof, wherein the infectivity of the virus is inhibited thereby treating the subject, and wherein the azide-modified carbohydrate is N-azidoacetylgalactosamine, N-azidoacetyl-D-mannosamine, N-azidoacetylglucosamine, tetraacetylated N-azidoacetylgalactosamine or tetraacetylated N-azidoacetylglucosamine.

2. The method of claim 1 , wherein the virus is a non-human animal virus or a human animal virus.

3. The method of claim 1 , wherein the virus is a plant virus.

4. The method of claim 1 , wherein the virus is an insect virus.

5. The method of claim 2 , wherein the human animal virus is an adenovirus, an astrovirus, a hepadnavirus, a herpesvirus, a papovavirus, a poxvirus, an arenavirus, a bunyavirus, a calcivirus, a coronavirus, a filovirus, a flavivirus, an orthomyxovirus, a paramyxovirus, a picornavirus, a reovirus, a retrovirus, a rhabdovirus, or a togavirus.

6. The method of claim 5 , wherein the retrovirus is a human immunodeficiency virus or a human T-lymphotrophic virus.

7. The method of claim 6 , wherein the retrovirus is the human immunodeficiency virus, HIV-1.

8. The method of claim 1 , wherein the subject is a human.

Assignees

• Life Technologies Corp
• Univ Johns Hopkins

Inventors

• Agnew Brian
• Graham David
• Singh Upinder
• Grecian Scott

Classifications

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K38/215

  IFN-beta · CPC title

• A61K31/655 Primary

  Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds · CPC title